Showing papers by "Joseph L. Izzo published in 1986"
TL;DR: In this animal DOCA administration produces a neurogenic form of hypertension which appears to be analogous to essential hypertension in man.
Abstract: To assess the mechanism responsible for maintaining the elevated arterial pressure in 2-kidney DOCA treated Yucatan miniature swine, cardiovascular parameters and the responses to hexamethonium bromide (HMB) were evaluated in normal and DOCA treated animals. Using chronically instrumented conscious animals, measurements of mean arterial pressure (MAP), cardiac output (CO), and calculated total peripheral resistance (TPR) revealed that with DOCA hypertension MAP was increased 50-60 mmHg above controls. This increased pressure was due to an increase in TPR with CO remaining normal. HMB normalized the MAP of the DOCA animals via a selective lowering of TPR to a value similar to that of the controls. In DOCA hypertensive animals these functional changes, due to increased peripheral sympathetic nerve activity, were reflected by significantly elevated plasma norepinephrine. In this animal DOCA administration produces a neurogenic form of hypertension which appears to be analogous to essential hypertension in man.
9 citations
TL;DR: Of six patients with chronic renal failure given enalapril maleate, 20 mg/day, all had increases in serum potassium levels of about 1 mEq/L, and two of six had significant hyperkalemia, which contrasts with the experience in 30 hypertensives with normal renal function, in whom no changes in serumassium levels occurred during one or more months of enalapse treatment.
Abstract: To the Editor.— We are enthusiastic about the use of angiotensin convertingenzyme (ACE) inhibitors in hypertension and congestive heart failure, not only because of their efficacy but also because of the high quality of life for patients using these drugs. However, of six patients with chronic renal failure (CRF) given enalapril maleate, 20 mg/day, all had increases in serum potassium levels of about 1 mEq/L, and two of six had significant hyperkalemia. This contrasts with our experience in 30 hypertensives with normal renal function, in whom no changes in serum potassium levels occurred during one or more months of enalapril maleate treatment, 20 to 80 mg/day. Hyperkalemia has also been reported in patients with CRF given very large doses of captopril, 1 and again in this study high serum potassium levels occurred only when low aldosterone levels and impaired renal potassium excretion were both present. Study.— The Table
8 citations